Ax­some shares rock­et up on a sur­prise win for late-stage Alzheimer’s ag­i­ta­tion study — but this is no easy layup

Shares of Ax­some Ther­a­peu­tics $AXSM shot up Mon­day morn­ing on the sur­prise news that its lead drug scored sta­tis­ti­cal­ly sig­nif­i­cant re­sults for Alzheimer’s ag­i­ta­tion, a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER